Vivesto AB (VIVE) - Net Assets

Latest as of March 2026: Skr166.56 Million SEK ≈ $17.92 Million USD

Based on the latest financial reports, Vivesto AB (VIVE) has net assets worth Skr166.56 Million SEK (≈ $17.92 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr177.85 Million ≈ $19.14 Million USD) and total liabilities (Skr11.29 Million ≈ $1.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VIVE goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr166.56 Million
% of Total Assets	93.65%
Annual Growth Rate	6.78%
5-Year Change	-77.34%
10-Year Change	-58.53%
Growth Volatility	51.64

Vivesto AB - Net Assets Trend (2004–2025)

This chart illustrates how Vivesto AB's net assets have evolved over time, based on quarterly financial data. See Vivesto AB (VIVE) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Vivesto AB (2004–2025)

The table below shows the annual net assets of Vivesto AB from 2004 to 2025. For live valuation and market cap data, see Vivesto AB market cap and net worth.

Year	Net Assets	Change
2025-12-31	Skr124.58 Million ≈ $13.41 Million	-21.32%
2024-12-31	Skr158.33 Million ≈ $17.04 Million	-19.96%
2023-12-31	Skr197.80 Million ≈ $21.29 Million	-39.22%
2022-12-31	Skr325.42 Million ≈ $35.02 Million	-40.80%
2021-12-31	Skr549.71 Million ≈ $59.16 Million	-19.95%
2020-12-31	Skr686.74 Million ≈ $73.90 Million	-16.19%
2019-12-31	Skr819.39 Million ≈ $88.18 Million	+93.23%
2018-12-31	Skr424.05 Million ≈ $45.63 Million	+22.90%
2017-12-31	Skr345.04 Million ≈ $37.13 Million	+14.87%
2016-12-31	Skr300.37 Million ≈ $32.32 Million	-7.88%
2015-12-31	Skr326.05 Million ≈ $35.09 Million	-13.22%
2014-12-31	Skr375.71 Million ≈ $40.43 Million	+33.27%
2013-12-31	Skr281.91 Million ≈ $30.34 Million	-11.67%
2012-12-31	Skr319.15 Million ≈ $34.35 Million	+16.70%
2011-12-31	Skr273.47 Million ≈ $29.43 Million	-7.04%
2010-12-31	Skr294.17 Million ≈ $31.66 Million	+107.45%
2009-12-31	Skr141.80 Million ≈ $15.26 Million	+131.68%
2008-12-31	Skr61.21 Million ≈ $6.59 Million	-5.56%
2007-12-31	Skr64.81 Million ≈ $6.97 Million	-41.24%
2006-12-31	Skr110.30 Million ≈ $11.87 Million	+87.27%
2005-12-31	Skr58.90 Million ≈ $6.34 Million	+87.58%
2004-12-31	Skr31.40 Million ≈ $3.38 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Vivesto AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 8400.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr53.80 Million	43.19%
Other Comprehensive Income	Skr4.62 Million	3.71%
Other Components	Skr2.03 Billion	1629.22%
Total Equity	Skr124.58 Million	100.00%

Vivesto AB Competitors by Market Cap

The table below lists competitors of Vivesto AB ranked by their market capitalization.

Company	Market Cap
Artemis Resources Ltd AU:ARV	$10.67 Million
Kiora Pharmaceuticals Inc NASDAQ:KPRX	$10.68 Million
Progressive Impact Corporation Bhd KLSE:7201	$10.70 Million
SSH GROUP LTD F:JRSA	$10.70 Million
BARRAMUNDI GROUP PTE. LTD F:95Z	$10.66 Million
SL Private Equity LSE:SLPE	$10.66 Million
Patriot Resources Ltd AU:PAT	$10.66 Million
B.A.G Films and Media Limited NSE:BAGFILMS	$10.66 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vivesto AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 158,328,000 to 124,577,000, a change of -33,751,000 (-21.3%).
Net loss of 34,082,000 reduced equity.
Other comprehensive income increased equity by 4,620,000.
Other factors decreased equity by 4,289,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-34.08 Million	-27.36%
Other Comprehensive Income	Skr4.62 Million	+3.71%
Other Changes	Skr-4.29 Million	-3.44%
Total Change	Skr-	-21.32%

Book Value vs Market Value Analysis

This analysis compares Vivesto AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 44.41x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 14.82x to 44.41x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-12-31	Skr0.60	Skr8.95	x
2005-12-31	Skr1.13	Skr8.95	x
2006-12-31	Skr2.09	Skr8.95	x
2007-12-31	Skr1.18	Skr8.95	x
2008-12-31	Skr1.08	Skr8.95	x
2009-12-31	Skr2.36	Skr8.95	x
2010-12-31	Skr4.06	Skr8.95	x
2011-12-31	Skr3.05	Skr8.95	x
2012-12-31	Skr2.88	Skr8.95	x
2013-12-31	Skr2.13	Skr8.95	x
2014-12-31	Skr2.56	Skr8.95	x
2015-12-31	Skr2.11	Skr8.95	x
2016-12-31	Skr1.66	Skr8.95	x
2017-12-31	Skr1.37	Skr8.95	x
2018-12-31	Skr1.44	Skr8.95	x
2019-12-31	Skr2.06	Skr8.95	x
2020-12-31	Skr-2.63	Skr8.95	x
2021-12-31	Skr1.23	Skr8.95	x
2022-12-31	Skr0.66	Skr8.95	x
2023-12-31	Skr0.32	Skr8.95	x
2024-12-31	Skr0.29	Skr8.95	x
2025-12-31	Skr0.20	Skr8.95	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vivesto AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -27.36%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.20x
Recent ROE (-27.36%) is above the historical average (-27.76%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	7.98%	22776190.91%	0.00x	1.15x	Skr-634.53K
2005	-12.41%	-856.40%	0.01x	1.08x	Skr-13.20 Million
2006	-8.86%	-43.58%	0.19x	1.10x	Skr-20.78 Million
2007	-7.83%	-7.12%	0.81x	1.35x	Skr-11.54 Million
2008	-11.63%	-8.95%	0.82x	1.59x	Skr-13.22 Million
2009	-12.03%	-55.48%	0.17x	1.27x	Skr-31.23 Million
2010	-22.42%	-62226.42%	0.00x	1.09x	Skr-95.38 Million
2011	-24.01%	-7370.37%	0.00x	1.28x	Skr-93.02 Million
2012	-22.68%	0.00%	0.00x	1.39x	Skr-104.30 Million
2013	-37.29%	-175186.67%	0.00x	1.66x	Skr-133.30 Million
2014	-31.27%	-5676.18%	0.00x	1.37x	Skr-155.07 Million
2015	-43.41%	-2220.92%	0.01x	1.58x	Skr-174.14 Million
2016	-53.35%	-93164.53%	0.00x	1.74x	Skr-190.28 Million
2017	-34.20%	-3723.79%	0.01x	1.65x	Skr-152.51 Million
2018	-40.33%	-8637.37%	0.00x	1.52x	Skr-213.42 Million
2019	-1.29%	-5.22%	0.20x	1.23x	Skr-92.47 Million
2020	0.00%	-5.22%	0.23x	0.00x	Skr111.85 Million
2021	-25.28%	-530.49%	0.04x	1.08x	Skr-193.92 Million
2022	-112.79%	-36160.59%	0.00x	1.09x	Skr-399.57 Million
2023	-65.09%	0.00%	0.00x	1.12x	Skr-148.52 Million
2024	-25.11%	0.00%	0.00x	1.09x	Skr-55.59 Million
2025	-27.36%	0.00%	0.00x	1.20x	Skr-46.54 Million

Industry Comparison

This section compares Vivesto AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $231,388,943
Average return on equity (ROE) among peers: -192.71%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Vivesto AB (VIVE)	Skr166.56 Million	7.98%	0.07x	$10.66 Million
BioGaia AB (publ) (BIOG-B)	$132.42 Million	27.28%	0.17x	$1.25 Billion
Enzymatica publ AB (ENZY)	$124.97 Million	-36.32%	0.26x	$65.83 Million
Enorama Pharma AB (ERMA)	$1.78 Million	-1345.02%	22.02x	$2.69 Million
Gabather AB (publ) (GABA)	$33.19 Million	-23.79%	0.05x	$2.48 Million
Klaria Pharma Holding AB (KLAR)	$69.42 Million	-77.12%	0.70x	$20.99 Million
Moberg Pharma AB (publ) (MOB)	$15.23 Million	-232.05%	0.48x	$46.74 Million
Nanexa AB (NANEXA)	$101.53 Million	-11.22%	0.36x	$77.75 Million
Newbury Pharmaceuticals AB (NEWBRY)	$68.77 Million	-21.33%	0.26x	$6.28 Million
Orexo AB (ORX)	$58.90 Million	-217.83%	12.35x	$79.38 Million
Swedish Orphan Biovitrum AB (publ) (SOBI)	$1.71 Billion	10.32%	0.60x	$16.38 Billion

About Vivesto AB

ST:VIVE Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$10.66 Million

Skr99.09 Million SEK

Market Cap Rank

#26876 Global

#589 in Sweden

Share Price

Skr8.95

Change (1 day)

+1.70%

52-Week Range

Skr0.08 - Skr17.00

All Time High

Skr17.00